{"id":"NCT03567057","sponsor":"Adamas Pharmaceuticals, Inc.","briefTitle":"A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment","officialTitle":"A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-07-18","primaryCompletion":"2020-11-17","completion":"2021-04-18","firstPosted":"2018-06-25","resultsPosted":"2022-01-18","lastUpdate":"2022-01-18"},"enrollment":424,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis","Walking Impairment"],"interventions":[{"type":"DRUG","name":"ADS-5102, 274 mg","otherNames":["amantadine extended release"]}],"arms":[{"label":"ADS-5102, 274 mg","type":"EXPERIMENTAL"}],"summary":"This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).","primaryOutcome":{"measure":"Number of Patients With Adverse Events","timeFrame":"Through study completion, an average of 1 year.","effectByArm":[{"arm":"Placebo/274 mg ADS-5102","deltaMin":122,"sd":null},{"arm":"137 mg ADS-5102/274 mg ADS-5102","deltaMin":116,"sd":null},{"arm":"274 mg ADS-5102/274 mg ADS-5102","deltaMin":86,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":92,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":159},"commonTop":["Oedema peripheral","Fall","Urinary tract infection","Livedo reticularis","Dry mouth"]}}